Clinical Trial · NCT06820333

The Clinical Impact and Prognostic Value of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer: Real-world Evidence from a Monocentric, Prospective Observational Study

Overview

The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.

Sponsor

Heinrich-Heine University

Phase

N/A

Contacts

Eduards Mamlins (MD)

eduards.mamlins@med.uni-duesseldorf.de

(+49)211 8108069

Emil Novruzov (MD)

emil.novruzov@med.uni-duesseldorf.de

(+49)211 8118540

ClinicalTrials.gov

NCT06820333

Drug / Compound

[18F] PSMA-1007

Isotope(s):

Target(s):

PSMA